Mereo BioPharma
MREO
28 hedge funds and large institutions have $38.1M invested in Mereo BioPharma in 2020 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 5 closing their positions.
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
73% more capital invested
Capital invested by funds: $22M → $38.1M (+$16.1M)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
17% more funds holding
Funds holding: 24 → 28 (+4)
1.28% less ownership
Funds ownership: 5.84% → 4.57% (-1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$15.9M |
| 2 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$4.31M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.5M |
| 4 |
JGC
J. Goldman & Co
New York
|
+$1.3M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
-$1.21M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$765K |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$612K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$265K |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$260K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LGM
26
Logos Global Management
San Francisco,
California
| – | -$612K | -200,000 | Closed |
|
27
UBS Group
Zurich,
Switzerland
| – | -$2.29K | -782 | -81% |
|
|
PAG
28
Private Advisor Group
Morristown,
New Jersey
| – | -$1K | -255 | Closed |
|
|
CCM
29
Chiron Capital Management
Tallahassee,
Florida
| – | +$111 | +38 | New |
|
MREO Hedge Fund Activity: Q3 2020 in Review
28 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q3 2020, worth a combined $38.1M — up 73% from $22M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new MREO positions and 5 closed out — a net gain of 4 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Vivo Capital, adding an estimated $15.9M. The largest seller was Verition Fund Management, exiting entirely with an estimated $1.21M sold.
- 28 institutional investors held Mereo BioPharma (MREO) as of Q3 2020, up from 24 in Q2 2020.
- Funds reported $38.1M of Mereo BioPharma stock for Q3 2020, up 73% quarter-over-quarter.
- 9 funds opened new Mereo BioPharma positions in Q3 2020 and 5 closed out, a net change of +4 holders.
- The largest Mereo BioPharma buyer in Q3 2020 was Vivo Capital, an estimated $15.9M added.
- The largest Mereo BioPharma seller in Q3 2020 was Verition Fund Management, an estimated $1.21M sold.
Based on aggregated 13F filings for Q3 2020.